Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19617 | 0.82 | — | — | |
| SCHEMBL1480536 | 0.82 | LTA4H (0.50) | ALDH1A1CA1LMNACA2L3MBTL1 | |
| SCHEMBL2363317 | 0.78 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL6546430 | 0.78 | MAOB (0.56) | HDAC1 | |
| SCHEMBL6546428 | 0.78 | MAOB (0.56) | HDAC1 | |
| SCHEMBL2839493 | 0.77 | ALDH1A1 (0.56) | ALDH1A1CA1MGLLTP53TAAR1 | |
| SCHEMBL76158 | 0.77 | CA1 (0.62) | ALDH1A1CA1MGLLTP53TAAR1 | |
| SCHEMBL9171323 | 0.77 | CA1 (0.62) | ALDH1A1CA1MGLLTP53TAAR1 | |
| SCHEMBL76159 | 0.77 | CA1 (0.62) | ALDH1A1CA1MGLLTP53TAAR1 | |
| Tannin Pyrogallol SCHEMBL21448 | 0.74 | ALDH1A1 (0.90) | ALDH1A1CA1MGLLTAAR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021215836-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING EYE DISEASES COMPRISING VERBENONE DERIVATIVE | 신풍제약주식회사 (KR) | 2021-10-28 | — | — | WO | claimed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | claimed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | claimed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | claimed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | claimed |
| JP-2006518738-A | — | — | 2006-08-17 | — | — | JP | claimed |
| EP-1638925-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-29 | — | — | EP | claimed |
| CN-1747936-A | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-03-15 | — | — | CN | claimed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | claimed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | claimed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | claimed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | claimed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | claimed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | claimed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | claimed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | claimed |
| WO-2021215836-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING EYE DISEASES COMPRISING VERBENONE DERIVATIVE | 신풍제약주식회사 (KR) | 2021-10-28 | — | — | WO | disclosed |
| EP-2421852-B9 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-01 | — | — | EP | disclosed |
| CN-102548983-B | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2014-09-17 | — | — | CN | disclosed |
| US-8815839-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-26 | — | — | US | disclosed |
| EP-2421852-B1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-07-18 | — | — | US | disclosed |
| CN-103052645-A | Functionalized polyhedral octavinylsilsesquioxanes | UNIV ADAM MICKIEWICZ | 2013-04-17 | — | — | CN | disclosed |
| US-8415341-B2 | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-09 | — | — | US | disclosed |
| CN-102548983-A | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2012-07-04 | — | — | CN | disclosed |
| EP-2421852-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| US-7851119-B2 | Electrophotographic photoconductor, method for producing the same, image forming process, image forming apparatus and process cartridge | RICOH COMPANY, LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| WO-2010124121-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITOR | JANSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| US-20080063962-A1 | ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, METHOD FOR PRODUCING THE SAME, IMAGE FORMING PROCESS, IMAGE FORMING APPARATUS AND PROCESS CARTRIDGE | RICOH COMPANY, LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070099958-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-05-03 | — | — | US | disclosed |
| EP-1638925-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-29 | — | — | EP | disclosed |
| CN-1747936-A | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA INC (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004110988-A1 | PROTEASE INHIBITORS | PROZYMEX A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1257265-B1 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | BIOAGENCY AG (DE) | 2004-01-21 | — | — | EP | disclosed |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | JOMAA PHARMAKA GMBH (DE) | 2003-02-20 | — | — | US | disclosed |
| EP-1257265-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | Jomaa Pharmaka GmbH (DE) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001070026-A2 | 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES | JOMAA PHARMAKA GMBH (DE) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001062709-A2 | USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | JOMAA PHARMAKA GMBH (DE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1068176-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | Jomaa, Hassan (DE) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000027803-A1 | CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS | JOMAA, HASSAN (DE) | 2000-05-18 | — | — | WO | disclosed |
| US-5770608-A | ANTICHOLESTEROL AGENTS FOR TREATING CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-06-23 | — | — | US | disclosed |
| US-5770608-A | ANTICHOLESTEROL AGENTS FOR TREATING CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324015-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | ALDH1A1 662/4885CA1 4879/4885MGLL 1/4885 |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | ALDH1A1 710/4885CA1 1363/4885MGLL 3347/4885 |
| US-20030036532-A1 | Use of 2-phenylene diamine derivatives for the treatment of infections | HRH2, ASPH, NQO2 | ALDH1A1 1419/4885CA1 4387/4885MGLL 463/4885 |
| US-20070099958-A1 | Protease inhibitors | CTSC, DPP7, BACE1 | ALDH1A1 3738/4885CA1 1184/4885MGLL 2729/4885 |
| US-20130184251-A1 | HETEROAROMATIC AND AROMATIC PIPERAZINYL AZETIDINYL AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPC | ALDH1A1 662/4885CA1 4879/4885MGLL 1/4885 |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | ALDH1A1 710/4885CA1 1363/4885MGLL 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.